Country for PR: China
Contributor: PR Newswire Asia (China)
Friday, January 28 2022 - 16:00
Ready to Enter the Middle East Market, Vazyme Showcases Its COVID-19 Testing Solutions at Medlab Middle East 2022
DUBAI, UAE, Jan. 28, 2022 /PRNewswire-AsiaNet/ --

Leading China-based biotech company Vazyme (688105.SH) participated in the 2022 
edition of Medlab Middle East in the Dubai World Trade Centre (DWTC) from 
January 24th to 27th, a leading laboratory and flagship exhibition and 
conference that brings together global medical communities to display the best 
laboratory innovation and technology. At Booth No. Z5.H20, the company 
showcased its full product portfolios for COVID-19 testing solutions, as well 
as advanced IVD products to online and in-person event visitors. Among the more 
than 500 visitors, most of them were from Middle East region and the rest were 
from India, Turkey, etc. The COVID-19 Antigen Rapid Self-Test Kit, which 
produces test result in 10 minutes and achieves a 99.81% accuracy, was the most 
popular product displayed.

"As the omicron variant starts to take hold, struggling hospitals and testing 
centers are under increased strain, underscoring the imperative to boost up the 
production of rapid and reliable COVID-19 test kits to track a new surging wave 
of infections. We wish to help the medical communities in the Middle East and 
Africa  region to address this issue by presenting our high-quality COVID-19 
testing products and solutions at Medlab 2022 as a part of our effort to 
strengthen local measures to combat the pandemic," said by Jenny Jiang, 
International Business Manager of Vazyme.

At the event, Vazyme's entire lineup of Nucleic Acid Detection Solutions was on 
full display, along with other products for COVID-19 detection that include 
series of Antigen Detection Kits, COVID-19 Vaccine Antibody evaluation 
solutions, and raw materials products of the detection solutions.  One of the 
highlights of its exhibition, Vazyme Automatic Nucleic Acids Extraction System, 
has obtained market approvals from the governments of UAE and Saudi Arabia, and 
its 2019-nCoV Triplex RT-qPCR Detection Kit has also been recently authorized 
to enter the UAE market.

Ten years into its existence, Vazyme has cemented its leadership in China's 
biotech industry with a sufficient production capacity of IVD production line 
equivalent to 1 million units per day. Vazyme's MENA-based team consists of IVD 
product experts who offer all-around services and one-to-one installment 
guidance to local consumers. Vazyme has ramped up its global expansion in 2021 
by setting up its first wholly-owned overseas subsidiary in Indonesia, with its 
offices and warehouses in the US, the EU, and Hong Kong SAR serving and 
supporting worldwide customers. 

"We will celebrate the 10th anniversary of our company since establishment this 
year. As a forerunner advancing innovation in life science, Vazyme's mission is 
to harness science and technology to improve health and life, addressing the 
global unmet medical needs while holding ourselves to the highest standards of 
ethics, accountability, and professionalism. Our R&D-centric approach allows us 
to constantly innovate and bring new products and solutions to our customers. 
We will continue to work with our partners across the globe, building on our 
previous efforts to strengthen medical abilities in the fight against severe 
illnesses," said by Jenny Jiang.

SOURCE  Vazyme

Image Attachments Links:


   Caption: Vazyme at Medlab Middle East 2022